PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES- HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.385
https://www.valueinhealthjournal.com/article/S1098-3015(18)33685-4/fulltext
Section Title :
Section Order :
2288
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33685-4&doi=10.1016/j.jval.2018.09.385